Heart Failure Leading to the Onglyza® Lawsuit
The prescription drug Onglyza® has been linked to potentially deadly health complications that affect type 2 diabetic patients. Patients have suffered cardiac problems and at least one patient has died after taking this drug to help control blood sugar. Our top-rated personal injury law firm is representing Onglyza® lawsuit plaintiffs in the San Diego, CA-area. If you or your loved one has experienced a complication from a dangerous medication, you are encouraged to seek legal counsel.
Our product liability attorneys handle cases for patients who have been injured by pharmaceutical treatments, including popular diabetes drugs Actos® and Invokana®. If you have been negatively affected by Onglyza® or another diabetes medication, please contact us today to schedule a free consultation.
Onglyza® (saxagliptin) is a DPP-4 inhibitor designed to control blood sugar in type 2 diabetic patients. Working similarly to other drugs that provide incretin-based therapy, the medicine stimulates the pancreas to secrete more insulin, and also inhibits the liver from producing excess sugar.
Approved by the Food and Drug Administration (FDA) in 2009, Onglyza® is a popular choice, considered effective without causing weight gain, a common side effect. In 2015, manufacturer AstraZeneca achieved sales of $786 million with Onglyza®. The corporation also makes Kombiglyze XR®, which combines saxagliptin with metformin (another diabetes drug).
Complications from Onglyza®
In April 2016, the FDA issued a safety alert warning patients of heart failure risks associated with Onglyza® and Kombiglyze XR®, as well as Nesina®, Kazano®, and Oseni®. This was in response to clinical studies linking heart failure to use of drugs that contain saxagliptin or alogliptin. One study reported in 2014 found a 27 percent increase in hospitalization for heart failure among patients taking saxagliptin.
Most patients taking Onglyza® have been unaware of this risk. In October 2015, a wrongful death lawsuit was filed against AstraZeneca alleging a patient taking Onglyza® died after suffering heart problems. The lawsuit accuses the corporation of marketing a defective drug and failing to warn patients and doctors about dangerous complications.
Hundreds of lawsuits are currently pending against manufacturers of other DPP-4 drugs linked to pancreatitis (inflammation of the pancreas) and pancreatic cancer. This is also of potential concern for Onglyza® patients. Pancreatitis has been listed as a side effect of Onglyza® since 2011. This condition can be very serious, and chronic pancreatitis has been shown to lead to pancreatic cancer in some cases.
Seeking Legal Help
The Onglyza® lawsuit is in the early stages, but is expected to grow as more patients and families learn about the drug’s connection to cardiac and pancreatic complications. This type of product liability litigation often leads to the formation of multidistrict litigation, which combines multiple cases under one judge to simplify the discovery process.
If you or a loved one suffered heart failure or were diagnosed with pancreatic cancer after taking Onglyza®, you may be eligible for compensation. Damages such as medical expenses, lost income, pain and suffering, and other losses can be covered by this type of litigation. Our attorneys have over three decades of experience and can provide outstanding representation for personal injury and wrongful death plaintiffs.
Our firm offers a free consultation and case review. We work on a contingency fee basis, so you pay no fees until a settlement or jury award is secured. Please contact us today to arrange to speak to an attorney.